Physician profile
Patrick D Bradley
NPI 1780909291
$1,497.36
in general payments reported to CMS, 2019-2025
18 companies · $367 in 2025
The $367 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $138 · 2020: $55.78 · 2021: $268 · 2022: $114 · 2023: $292 · 2024: $263 · 2025: $367.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $922.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $921.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $284.50 | 2019-2025 | Eylea Hd, Eylea |
| Rxsight INC | $180.55 | 2023-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens, Rxsight Injector Cartridge |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $164.14 | 2019-2021 | |
| Apellis Pharmaceuticals, INC. | $128.80 | 2023-2025 | Syfovre |
| Alcon Vision LLC | $117.82 | 2024-2025 | Lensx, Hydrus Microstent, Rocklatan |
| Abbvie INC. | $99.37 | 2022-2024 | Durysta, Ozurdex |
| Allergan, INC. | $98.95 | 2020-2022 | |
| Genentech USA, INC. | $77.61 | 2022-2024 | Vabysmo |
| Bausch & Lomb Americas INC. | $70.76 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Astellas Pharma US INC | $64.72 | 2025 | Izervay |
| Alimera Sciences, INC. | $57.21 | 2021 | |
| Aerie Pharmaceuticals, INC. | $42.40 | 2019 | |
| Carl Zeiss Meditec USA, INC. | $27.72 | 2022 | |
| Glaukos Corporation | $20.07 | 2025 | Idosetr |
| Shire North American Group INC | $19.98 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $16.14 | 2021 | |
| Novartis Pharmaceuticals Corporation | $13.71 | 2019 | |
| Boston Scientific Corporation | $12.91 | 2023 | Wavewriter Alpha Prime 16 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Bradley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.